Alice M. Turner

List of Publications by Year
in descending order

179 papers	4,436 citations	109321 35 h-index	123424 61 g-index
249 all docs	249 docs citations	249 times ranked	5726 citing authors

#	Article	IF	Citations
1	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423.	12.1	28
2	Cost-effectiveness of domiciliary non-invasive ventilation in patients with chronic obstructive pulmonary disease. Thorax, 2022, 77, 976-986.	5.6	8
3	Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. Npj Primary Care Respiratory Medicine, 2022, 32, 6.	2.6	9
4	A Systematic Review of Nudge Interventions to Optimize Medication Prescribing. Frontiers in Pharmacology, 2022, 13, 798916.	3.5	10
5	Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group. International Journal of COPD, 2022, Volume 17, 53-64.	2.3	4
6	A human factors approach to quality improvement in oxygen prescribing. Clinical Medicine, 2022, 22, 153-159.	1.9	4
7	Chronic Obstructive Pulmonary Disease: The Present and Future. Biomedicines, 2022, 10, 499.	3.2	6
8	Automated conflict resolution for patients with multiple morbidity being treated using more than one set of single condition clinical guidance: A case study. Computers in Biology and Medicine, 2022, 144, 105381.	7.0	0
9	A Systematic Review and Meta-Analysis of the Prevalence and Impact of Pulmonary Bacterial Colonisation in Stable State Chronic Obstructive Pulmonary Disease (COPD). Biomedicines, 2022, 10, 81.	3.2	5
10	Pulmonary function test and computed tomography features during follow-up after SARS, MERS and COVID-19: a systematic review and meta-analysis. ERJ Open Research, 2022, 8, 00056-2022.	2.6	14
11	Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review. Thorax, 2022, 77, 939-945.	5.6	18
12	Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration. Archivos De Bronconeumologia, 2022, 58, 840-842.	0.8	4
13	Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 162-176.	0.7	4
14	Small Airways Disease, Biomarkers and COPD: Where are We?. International Journal of COPD, 2021, Volume 16, 351-365.	2.3	14
15	Development and Relevance of Hypercapnia in COPD. Canadian Respiratory Journal, 2021, 2021, 1-8.	1.6	11
16	FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD. BMJ Open, 2021, 11, e042526.	1.9	2
17	Colour vision deficiency and sputum colour charts in COPD patients: an exploratory mixed-method study. Npj Primary Care Respiratory Medicine, 2021, 31, 13.	2.6	0
18	Nephrotic syndrome secondary to alpha-1 antitrypsin deficiency. BMJ Case Reports, 2021, 14, e240288.	0.5	0

#	Article	IF	Citations
19	Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. European Respiratory Journal, 2021, 58, 2004240.	6.7	58
20	Long-term effect of Î±1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database. ERJ Open Research, 2021, 7, 00194-2021.	2.6	4
21	Pulmonary MicroRNA Changes Alter Angiogenesis in Chronic Obstructive Pulmonary Disease and Lung Cancer. Biomedicines, 2021, 9, 830.	3.2	9
22	Effects of short-term graded dietary carbohydrate intake on intramuscular and whole body metabolism during moderate-intensity exercise. Journal of Applied Physiology, 2021, 131, 376-387.	2.5	5
23	Accuracy and cost-effectiveness of different screening strategies for identifying undiagnosed COPD among primary care patients (â‰¥40 years) in China: a cross-sectional screening test accuracy study: findings from the Breathe Well group. BMJ Open, 2021, 11, e051811.	1.9	9
24	Bilevel positive airway pressure ventilation for non-COPD acute hypercapnic respiratory failure patients: A systematic review and meta-analysis. Annals of Thoracic Medicine, 2021, 16, 306.	1.8	3
25	Relationship between Depression and Anxiety, Health Status and Lung Function in Patients with Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 621-629.	1.6	2
26	The impact of <scp>COVID</scp>â€19 on acute nonâ€invasive ventilation services: A case for change. Respirology, 2021, 26, 1106-1109.	2.3	5
27	Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. International Journal of COPD, 2021, Volume 16, 2983-2996.	2.3	8
28	Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency. Expert Review of Precision Medicine and Drug Development, 2021, 6, 65-78.	0.7	0
29	Unravelling the risk of (intermediate) antitrypsin deficiency. Thorax, 2021, 76, 214-215.	5.6	0
30	Respiratory Physiological Sequelae following Coronavirus Infection: A Systematic Review. , 2021, , .		0
31	Thoracic Radiological SequelaeÂafter Coronavirus Infection: A Systematic Review. , 2021, , .		0
32	Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients. , 2021, , .		0
33	Late Breaking Abstract - COVID-19 Infodemic and Health-Related Quality of Life (HRQoL) in Patients with Chronic Respiratory Diseases (CRDs). , 2021, , .		0
34	Baseline characteristics of patients enrolled in the EARCO prospective registry of alpha-1 antitrypsin deficiency: preliminary results. , 2021, , .		0
35	Case-finding and improving patient outcomes for chronic obstructive pulmonary disease in primary care: the BLISS research programme including cluster RCT. Programme Grants for Applied Research, 2021, 9, 1-148.	1.0	1
36	Prevalence, Pattern, Risks Factors and Consequences of Antibiotic Resistance in COPD: A Systematic Review. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 672-682.	1.6	5

#	Article	IF	Citations
37	Ward-Based Noninvasive Ventilation for Acute Hypercapnic Respiratory Failure Unrelated to Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal, 2021, 2021, 1-7.	1.6	4
38	Modernising case finding for Î±₁-antitrypsin deficiency by DNA sequencing of COPD patients. European Respiratory Journal, 2020, 56, 2002628.	6.7	0
39	Pneumonia in exacerbations of COPD: what is the clinical significance?. ERJ Open Research, 2020, 6, 00282-2019.	2.6	8
40	Sex differences between women and men with COPD: A new analysis of the 3CIA study. Respiratory Medicine, 2020, 171, 106105.	2.9	50
41	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020.	2.6	10
42	What Do Alpha-1 Antitrypsin Levels Tell Us About Chronic Inflammation in COPD?. Archivos De Bronconeumologia, 2020, 56, 72-73.	0.8	0
43	Protocol for the EARCO Registry: a pan-European observational study in patients with Î±₁-antitrypsin deficiency. ERJ Open Research, 2020, 6, 00181-2019.	2.6	20
44	What Do Alpha-1 Antitrypsin Levels Tell Us About Chronic Inflammation in COPD?. Archivos De Bronconeumologia, 2020, 56, 72-73.	0.8	14
45	Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough. , 2020, , .		7
46	Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 280-289.	0.7	3
47	Determinants of arterial stiffness in Alpha-1 Antitrypsin Deficiency. , 2020, , .		0
48	Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives . Therapeutics and Clinical Risk Management, 2020, Volume 16, 1243-1255.	2.0	10
49	Liver Disease in Alpha-1-Antitrypsin Deficiency. , 2020, , 377-389.		0
50	Personalising exacerbation prediction strategies in chronic obstructive pulmonary disease. World Journal of Respirology, 2020, 10, 11-16.	0.5	1
51	Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Faculty Reviews, 2020, 9, 1.	3.9	1
52	A multicentre observational study of the prevalence, management and outcomes of subsegmental pulmonary embolism. , 2020, , .		0
53	Identification of important respiratory research themes relevant to primary care: qualitative analysis of round 1 of the 2020 International Primary Care Respiratory Group (IPCRG) Research Prioritisation Exercise. , 2020, , .		0
54	Tackling COPD misdiagnosis in primary care through integrated care. , 2020, , .		0

#	Article	IF	Citations
55	Research priorities in alpha-1 antitrypsin deficiency (AATD) for healthcare professionals. , 2020, , .		0
56	Sex differences in COPD outcome in 5,355 women with COPD: A new analysis of the 3CIA study. , 2020, , .		0
57	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging systems: a pooled analysis of individual patient data. , 2020, , .		0
58	Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Faculty Reviews, 2020, 9, 1.	3.9	8
59	Alpha 1 antitrypsin deficiency: a rare multisystem disease, predominantly affecting the lung. Expert Opinion on Orphan Drugs, 2019, 7, 315-326.	0.8	0
60	External Validation Of The Updated ADO Score In COPD Patients From The Birmingham COPD Cohort . International Journal of COPD, 2019, Volume 14, 2395-2407.	2.3	6
61	Identifying the at risk smokers: who goes on to get COPD?. European Respiratory Journal, 2019, 54, 1901613.	6.7	1
62	Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care. Thorax, 2019, 74, 730-739.	5.6	22
63	Predicting Postoperative Lung Function Following Lung Cancer Resection: A Systematic Review and Meta-analysis. EClinicalMedicine, 2019, 15, 7-13.	7.1	18
64	Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opinion on Investigational Drugs, 2019, 28, 891-902.	4.1	17
65	Temporal trends in survival following wardâ€based NIV for acute hypercapnic respiratory failure in patients with COPD. Clinical Respiratory Journal, 2019, 13, 184-188.	1.6	8
66	Interventions to Increase the Rate of Influenza and Pneumococcal Vaccination in Patients with Chronic Obstructive Pulmonary Disease: A Scoping Review. Medicina (Lithuania), 2019, 55, 277.	2.0	1
67	Memory, attention and fluency deficits in COPD may be a specific form of cognitive impairment. ERJ Open Research, 2019, 5, 00229-2018.	2.6	10
68	Experience-based co-design to improve a pulmonary rehabilitation programme. International Journal of Health Care Quality Assurance, 2019, 32, 778-787.	0.9	6
69	Late presentation of acute hypercapnic respiratory failure carries a high mortality risk in COPD patients treated with ward-based NIV. Respiratory Medicine, 2019, 151, 128-132.	2.9	7
70	Diagnosis and management of Î±1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Research, 2019, 5, 00171-2018.	2.6	36
71	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17.	1.6	7
72	The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency. European Respiratory Journal, 2019, 53, 1900138.	6.7	32

#	Article	IF	Citations
73	Interventions for the management and prevention of sarcopenia in the critically ill: A systematic review. Journal of Critical Care, 2019, 50, 287-295.	2.2	39
74	The association between asthma and obstructive sleep apnea (OSA): A systematic review. Journal of Asthma, 2019, 56, 118-129.	1.7	40
75	Development of the Birmingham Lung Improvement Studies (BLISS) prognostic score for COPD patients in primary care: data from the Birmingham COPD cohort. , 2019, , .		1
76	Treatment of lung disease in patients with AATD. , 2019, , 78-92.		1
77	Alpha-1 Antitrypsin Deficiency: A Predisposing Factor for the Development of Pulmonary Langerhans Cell Histiocytosis. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 206-209.	0.7	3
78	Effect of screening for undiagnosed COPD on respiratory hospitalisation and mortality; 4 year follow up of the TargetCOPD trial. , 2019, , .		0
79	Risk charts of five-year mortality in COPD patients. , 2019, , .		0
80	Comparison of outcomes in augmentation naÃ¯ve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. , 2019, , .		1
81	External validation of the updated ADO score to predict mortality in COPD patients from the Birmingham COPD cohort. , 2019, , .		1
82	Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. Journal of Hepatology, 2018, 69, 378-384.	3.7	56
83	Systematic review: the natural history of alphaâ€1 antitrypsin deficiency, and associated liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 877-885.	3.7	67
84	ICS Use May Modify FEV₁ Decline in Î±₁-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils. Respiration, 2018, 95, 114-121.	2.6	11
85	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33.	5.5	21
86	Correction: P117 Neutrophil chemotaxis in the sz form of alpha-1 antitrypsin deficiency. Thorax, 2018, 73, 400-400.	5.6	0
87	Can process mining automatically describe care pathways of patients with long-term conditions in UK primary care? A study protocol. BMJ Open, 2018, 8, e019947.	1.9	14
88	ISQUA18-2485A Patient-Centred Approach to Redesigning Information Sources and Flows of a Pulmonary Rehabilitation Services. International Journal for Quality in Health Care, 2018, 30, 40-41.	1.8	0
89	Automated conflict resolution between multiple clinical pathways: a technology report. BMJ Health and Care Informatics, 2018, 25, 142-148.	3.0	1
90	P2.06-28 Assessment of Chest Wall Motion Using Structured Light Plethysmography (SLP) in Mesothelioma and Benign Pleural Disease. Journal of Thoracic Oncology, 2018, 13, S753.	1.1	0

#	Article	IF	Citations
91	Ward-Based Non-Invasive Ventilation in Acute Exacerbations of COPD: A Narrative Review of Current Practice and Outcomes in the UK. Healthcare (Switzerland), 2018, 6, 145.	2.0	10
92	Does Continuous Positive Airway Pressure (CPAP) treatment of obstructive sleep apnoea (OSA) improve asthma-related clinical outcomes in patients with co-existing conditions?- A systematic review. Respiratory Medicine, 2018, 143, 18-30.	2.9	30
93	Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. Expert Review of Gastroenterology and Hepatology, 2018, 12, 745-747.	3.0	10
94	CT densitometry in emphysema: a systematic review of its clinical utility. International Journal of COPD, 2018, Volume 13, 547-563.	2.3	39
95	Health status decline in Î±-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?. Respiratory Research, 2018, 19, 137.	3.6	12
96	Letter: unlikely liver bedfellowsâ€"alphaâ€1 antitrypsin deficiency and granulomatosis with polyangiitis. Author's reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 233-233.	3.7	0
97	Early ward-based acute noninvasive ventilation: a paper that changed practice. Breathe, 2018, 14, 153-155.	1.3	9
98	Evolving indications and demographics for domiciliary Non-Invasive Ventilation (NIV) at an acute hospital based NIV service. , 2018, , .		1
99	Managing panniculitis in alpha-1 antitrypsin deficiency: Systematic review of evidence behind treatment. World Journal of Dermatology, 2018, 7, 1-8.	0.5	7
100	Using a rapid prioritisation process to identify health research priorities in LMICs. , 2018, , .		2
101	The impact of late presentation of acidotic hypercapnic respiratory failure in hospitalised COPD patients on outcome following non-invasive ventilation.. , 2018, , .		0
102	Cohort Profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) Cohort Study. International Journal of Epidemiology, 2017, 46, dyv350.	1.9	21
103	The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD). Respiratory Research, 2017, 18, 20.	3.6	76
104	IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer. European Respiratory Journal, 2017, 49, 1600711.	6.7	16
105	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	6.7	53
106	Assessing the extent of drug interactions among patients with multimorbidity in primary and secondary care in the West Midlands (UK): a study protocol for the Mixed Methods Multimorbidity Study (MiMMS). BMJ Open, 2017, 7, e016713.	1.9	4
107	European Respiratory Society statement: diagnosis and treatment of pulmonary disease in Î±₁-antitrypsin deficiency. European Respiratory Journal, 2017, 50, 1700610.	6.7	244
108	Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. International Journal of COPD, 2017, Volume 12, 1295-1308.	2.3	64

#	Article	IF	Citations
109	Physician perspectives: barriers to diagnosing and treating severe AATD. , 2017, , .		0
110	Decline in health status in alpha1 antitrypsin deficiency. , 2017, , .		0
111	Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. , 2017, , .		1
112	Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?. International Journal of COPD, 2016, Volume 11, 1745-1756.	2.3	39
113	Self-management of health care behaviors for COPD: a systematic review and meta-analysis. International Journal of COPD, 2016, 11, 305.	2.3	53
114	The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalized patients with COPD: a systematic review and meta-analysis. International Journal of COPD, 2016, Volume 11, 2269-2286.	2.3	32
115	Ventilatory responses to muscle metaboreflex activation in chronic obstructive pulmonary disease. Journal of Physiology, 2016, 594, 6025-6035.	2.9	20
116	Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial. Lancet Respiratory Medicine,the, 2016, 4, 720-730.	10.7	63
117	Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD. Respiratory Research, 2016, 17, 34.	3.6	11
118	Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respiratory Medicine, 2016, 112, 81-87.	2.9	36
119	British Thoracic Society community-acquired pneumonia care bundle: results of a national implementation project: TableÂ1. Thorax, 2016, 71, 288-290.	5.6	23
120	Ambulatory Oxygen for Exercise-Induced Desaturation and Dyspnea in Chronic Obstructive Pulmonary Disease (COPD): Systematic Review and Meta-Analysis. Chronic Obstructive Pulmonary Diseases (Miami,) Tj ETQq0 0 0 rgBT /Overlock 1	0.7	
121	Vitamin D supplementation in health and latent tuberculosis promotes regulatory T cell expression. , 2016, , .		0
122	Vitamin D binding protein (DBP) levels during tuberculosis treatment are affected by DBP genotype / haplotype but not by total vitamin D levels. , 2016, , .		0
123	Vitamin D supplementation in health and latent tuberculosis significantly influences T lymphocyte cytokine response. , 2016, , .		0
124	Systematic review of the relevance of CT densitometry in patients with COPD and AATD. , 2016, , .		0
125	Supported self-management for patients with COPD who have recently been discharged from hospital: a systematic review and meta-analysis. International Journal of COPD, 2015, 10, 853.	2.3	28
126	Visualization and quantitation of GLUT4 translocation in human skeletal muscle following glucose ingestion and exercise. Physiological Reports, 2015, 3, e12375.	1.7	18

#	Article	IF	Citations
127	The role of iron in pulmonary pathology. Multidisciplinary Respiratory Medicine, 2015, 10, 34.	1.5	26
128	A care-bundles approach to improving standard of care in AECOPD admissions: results of a national project: TableÂ1. Thorax, 2015, 70, 992-994.	5.6	29
129	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respiratory Medicine,the, 2015, 3, 443-450.	10.7	125
130	PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax, 2015, 70, 939-945.	5.6	64
131	Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax, 2015, 70, 617-624.	5.6	258
132	Adapting to domiciliary non-invasive ventilation in chronic obstructive pulmonary disease: A qualitative interview study. Palliative Medicine, 2015, 29, 268-277.	3.1	18
133	Clinically relevant subgroups in COPD and asthma. European Respiratory Review, 2015, 24, 283-298.	7.1	35
134	Identification of novel vascular targets in lung cancer. British Journal of Cancer, 2015, 112, 485-494.	6.4	25
135	Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Health Technology Assessment, 2015, 19, 1-516.	2.8	64
136	The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-246.	2.8	21
137	Genetic influences on lung function decline in AATD. , 2015, , .		0
138	TargetCOPD: A pragmatic randomised controlled trial of targeted case finding for COPDversusroutine practice in primary care. , 2015, , .		0
139	Blood eosinophils as a biomarker in alpha 1 anti trypsin deficiency. , 2015, , .		0
140	TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versusroutine practice in primary care: protocol. BMC Pulmonary Medicine, 2014, 14, 157.	2.0	16
141	Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease Strategy to Clinically Relevant Outcomes in Individuals with Î±1-Antitrypsin Deficiency. Annals of the American Thoracic Society, 2014, 11, 859-864.	3.2	10
142	Serum free light chains and the adaptive immune response in usual and alpha-1-antitrypsin deficiency-related chronic obstructive pulmonary disease. Lancet, The, 2014, 383, S28.	13.7	1
143	Utility of respiratory wardâ€based <scp>NIV</scp> in acidotic hypercapnic respiratory failure. Respirology, 2014, 19, 1241-1247.	2.3	22
144	The Early Mobility Bundle: a simple enhancement of therapy which may reduce incidence of hospital-acquired pneumonia and length of hospital stay. Journal of Hospital Infection, 2014, 88, 34-39.	2.9	62

#	Article	IF	Citations
145	Evaluation of oxygen prescription in relation to hospital admission rate in patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2014, 14, 127.	2.0	21
146	Protocol for a systematic review and economic evaluation of the clinical and cost-effectiveness of non-hospital-based non-invasive ventilation (NIV) in patients with stable end-stage COPD with hypercapnic respiratory failure. Systematic Reviews, 2014, 3, 32.	5.3	10
147	Î±-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine, 2014, 20, 105-115.	6.7	76
148	Spirometric and Gas Transfer Discordance in Î±1-Antitrypsin Deficiency. Chest, 2014, 145, 1316-1324.	0.8	18
149	Alpha-1 Antitrypsin Deficiency: New Developments in Augmentation and Other Therapies. BioDrugs, 2013, 27, 547-558.	4.6	13
150	Tuberculosis Incidence Correlates with Sunshine: An Ecological 28-Year Time Series Study. PLoS ONE, 2013, 8, e57752.	2.5	74
151	MUC5B: a good target for future therapy in pulmonary fibrosis?. Thorax, 2013, 68, 401-401.	5.6	3
152	Fifty Years On: GWAS Confirms the Role of a Rare Variant in Lung Disease. PLoS Genetics, 2013, 9, e1003768.	3.5	3
153	Pharmacotherapies for COPD. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2013, 7, CCRPM.S7211.	0.9	40
154	Molecular Determinants of Acute Muscle Wasting in the ICU. Critical Care Medicine, 2013, 41, 1141-1142.	0.9	2
155	Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. European Respiratory Journal, 2013, 41, 410-416.	6.7	28
156	Global Initiative for Chronic Obstructive Lung Disease 2011 Symptom/Risk Assessment in Î± 1 -Antitrypsin Deficiency. Chest, 2013, 144, 1152-1162.	0.8	16
157	Reforming respiratory outpatient services: a before-and-after observational study assessing the impact of a quality improvement project applying British Thoracic Society criteria to the discharge of patients to primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 72-78.	2.3	4
158	Vitamin D Deficiency and Acute Lung Injury. Inflammation and Allergy: Drug Targets, 2013, 12, 253-261.	1.8	43
159	The ventilatory response to muscle metaboreflex stimulation in patients with COPD. FASEB Journal, 2013, 27, 712.3.	0.5	0
160	Availability of 25-Hydroxyvitamin D3 to APCs Controls the Balance between Regulatory and Inflammatory T Cell Responses. Journal of Immunology, 2012, 189, 5155-5164.	0.8	172
161	Variability of sputum inflammatory mediators in COPD and Î±₁-antitrypsin deficiency. European Respiratory Journal, 2012, 40, 561-569.	6.7	38
162	A novel model and molecular therapy for Z alpha-1 antitrypsin deficiency. Mammalian Genome, 2012, 23, 241-249.	2.2	11

#	Article	IF	Citations
163	Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax, 2011, 66, 205-210.	5.6	97
164	Auto-Antibodies and Inflammation. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 959-960.	5.6	4
165	Smoke exposure as a determinant of autoantibody titre in Â1-antitrypsin deficiency and COPD. European Respiratory Journal, 2011, 37, 32-38.	6.7	52
166	Metalloproteinases in idiopathic pulmonary fibrosis. European Respiratory Journal, 2011, 38, 1461-1467.	6.7	130
167	Re-evaluating COPD Risk. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 837-838.	5.6	1
168	ANCA-associated vasculitis is linked to carriage of the Z allele of Î±₁ antitrypsin and its polymers. Annals of the Rheumatic Diseases, 2011, 70, 1851-1856.	0.9	69
169	Outdoor air pollution is associated with rapid decline of lung function in Â-1-antitrypsin deficiency. Occupational and Environmental Medicine, 2010, 67, 556-561.	2.8	35
170	CTLA4 polymorphisms and COPD. European Respiratory Journal, 2010, 35, 457-458.	6.7	4
171	Tumor Necrosis Factorâ€“Î± rs361525 Polymorphism Is Associated with Increased Local Production and Downstream Inflammation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 192-199.	5.6	48
172	The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax, 2010, 65, 456-462.	5.6	166
173	Rate of progression of lung function impairment in Â1-antitrypsin deficiency. European Respiratory Journal, 2009, 33, 1338-1344.	6.7	86
174	Outdoor air pollution is associated with disease severity in Â1-antitrypsin deficiency. European Respiratory Journal, 2009, 34, 346-353.	6.7	20
175	Phenotypic Differences in Alpha 1 Antitrypsin-Deficient Sibling Pairs May Relate to Genetic Variation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 353-359.	1.6	28
176	Alpha One Antitrypsin Deficiency: From Gene to Treatment. Respiration, 2007, 74, 481-492.	2.6	74
177	The genetics of chronic obstructive pulmonary disease. Respiratory Research, 2006, 7, 130.	3.6	68
178	Relationship of Sputum Color to Nature and Outpatient Management of Acute Exacerbations of COPD. Chest, 2000, 117, 1638-1645.	0.8	462
179	Respiratory Sequelae Following SARS, MERS, and COVID-19: A Systematic Review and Meta-Analysis of Pulmonary Function Tests and CT Features. SSRN Electronic Journal, 0, , .	0.4	0